RxDoctor Payments Data

Ramon Ortiz Espinal, MD

Nephrology · Jupiter, FLNPI 1215369129

Payments from drug & device makers

$893in general payments, 2019–2025

Across 29 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$184
  • Otsuka America Pharmaceutical, Inc.$105
  • OPKO Pharmaceuticals, LLC$97
  • Boehringer Ingelheim$88
  • Travere Therapeutics, Inc.$87
  • Akebia Therapeutics Inc$80
  • plus $252 from 6 others

What the payments were for

  • Food & beverage$86897%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$208,882
Medicare patients
526
Services billed
2,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$50,202
FarxigaDapagliflozin Propanediol49$30,145
KerendiaFinerenone17$19,658
ProsolParenteral Amino Acid 20% No.133$5,595
Nifedipine ErNifedipine11$1,212
Chlorthalidone53$1,008
Sevelamer Carbonate11$954
Losartan Potassium67$687
Tacrolimus11$458
Valsartan11$387
Calcitriol62$382
Amlodipine Besylate33$250
Famotidine24$225
Lisinopril39$202
Furosemide22$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$88$50,20269 claims
AstraZenecaFarxiga$33$30,14549 claims
BayerKerendia$31$19,65817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 756 nephrology providers in Florida.

Other nephrology in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →